Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II Study (PACIFIC BRAZIL)

NCT04230408 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT04230408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II Study (PACIFIC BRAZIL)
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
March 5, 2021
Completion date
December 20, 2024
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms